Reports Q2 revenue $250,000, consensus $1.67M. “We remain focused on exploring strategic alternatives and partnerships across our portfolio to enhance long-term shareholder value, as exemplified by our recent worldwide licensing agreement with Debiopharm for lunresertib and out-licensing of early-stage discovery platforms to DCx,” said Steve Forte, President, Chief Executive Officer and Chief Financial Officer of Repare. “In parallel to evaluating these strategic opportunities for our remaining programs, we expect to deliver initial data from the LIONS and POLAR trials in the fourth quarter.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPTX:
- Repare Therapeutics Signs Licensing Deal with Debiopharm
- Closing Bell Movers: Victory Capital gains on S&P 400 inclusion
- Repare Therapeutics enters licensing pact with Debiopharm for Lunresertib
- Repare Therapeutics Updates Severance Benefits for Executives
- Repare Therapeutics Holds Annual Shareholder Meeting